nostoxanthin | 29307-44-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: nostoxanthin
• 英文别名: (1R,2R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R,5R)-4,5-dihydroxy-2,6,6-trimethylcyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,3,5-trimethylcyclohex-4-ene-1,2-diol
• CAS: 29307-44-6
• 化学式: C₄₀H₅₆O₄
• 分子量: 600.882
• InChiKey: JVPASJUYZJKFHY-HWFHZMFDSA-N

物化性质

• 沸点：
  742.3±60.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  44
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  nostoxanthin 在 吡啶 、 氯磺酸 作用下， 反应 2.0h， 生成 nostoxanthin monosulfate 、 nostoxanthin disulfate 、 nostoxanthin trisulfate 、 nostoxanthin tetrasulfate
  参考文献：
  名称：

  Hertzberg, Sissel; Liaaen-Jensen, Synnoeve, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1985, vol. 39, # 8, p. 629 - 638

  摘要：

  DOI：

文献信息

• Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
  申请人：Cardax Pharmaceuticals, Inc.

  公开号：US07375133B2

  公开（公告）日：2008-05-20

  A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.

  一种抑制和/或改善与反应性氧化物种、反应性氮物种、自由基和/或非自由基有关的疾病发生的方法，其中给予受试者类胡萝卜素类似物或衍生物，单独或与另一类胡萝卜素类似物或衍生物或共同抗氧化剂配方结合使用。该类似物或衍生物的给予使得受试者发生与反应性氧化物种、反应性氮物种、自由基和/或非自由基有关的疾病的风险减少。该类似物或类似物组合可用于抑制和/或改善任何涉及反应性氧化物种、反应性氮物种、自由基和/或非自由基产生的疾病。在某些实施例中，该发明可能包括包括类胡萝卜素类似物或衍生物的药物组合物。类胡萝卜素类似物可能包括具有7到14个双键的共轭多烯。共轭多烯可能包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环中可能包括至少一个取代基。该取代基可能通过醚功能与环状环耦合。在某些实施例中，药物组合物可能包括生物学上不活性的载体。该药物组合物可能适用于人类受试者的给予。